Craniopharyngiomas are rare histologically benign but clinically challenging neoplasms. To obtain further information on the molecular genetics and biology of craniopharyngiomas, we analyzed a cohort of 121 adamantinomatous and 16 papillary craniopharyngiomas (ACP, PCP). We extracted DNA from formalin-fixed paraffin-embedded tissue and determined mutational status of CTNNB1, BRAF, and DDX3X by Sanger sequencing, next generation panel sequencing, and pyrosequencing. Sixteen craniopharyngiomas were further analyzed by molecular inversion profiling (MIP); 76.1% of the ACP were mutated in exon 3 of CTNNB1 encoding for b-catenin and there was a trend towards a worse event-free survival in cases mutated at Thr41. Next generation panel sequencing of 26 ACP did not detect any recurrent mutations other than CTNNB1 mutations. BRAF V600E mutations were found in 94% of the PCP, but not in ACP. GISTIC analysis of MIP data showed no significant larger chromosomal aberrations but a fraction of ACP showed recurrent focal gains of chromosomal material, other cases showed loss in the chromosomal region Xq28, and a third group and the PCP had stable genomes. In conclusion, the crucial pathogenetic event appears to be WNT activation in ACP, whereas it appears to be activation of the Ras/Raf/MEK/ERK pathway by BRAF V600E mutations in PCP.
INTRODUCTION
Craniopharyngiomas (CPs) are rare benign tumors of the sellar and parasellar region and account for approximately 2%-5% of all primary intracranial neoplasms. This nonglial epithelial tumor entity can be divided into the adamantinomatous (ACP) and papillary (PCP) subtypes. ACPs are more common and can be diagnosed at any age but mostly affect children under age 15 and adults between 50 and 74 years; PCPs are usually found in adults (1) (2) (3) . While the solid and homogenous PCPs consist of well-differentiated squamous epithelium, histological features of ACP are palisading epithelial cells, the so-called "wet keratin" (remnants of cells with pale nuclei embedded within an eosinophilic keratinous mass), and calcifications (1) . The 10-year recurrence-free survival for patients with ACP varies between 60% and 90% being mainly dependent by the extent of surgical resection.
In addition to the histomorphological differences, ACPs are characterized by activated WNT signaling indicated in subgroups of tumor cells showing nuclear b-catenin accumulation as a diagnostic feature. This activation, which is suggested to promote tumor cell migration (4) and might also represent the driving force in ACP tumorigenesis, is mainly caused by activating mutations of the CTNNB1 gene encoding for b-catenin; such mutations are reported in 16%-100% of ACP (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The CTNNB1 mutations are exclusively found in exon 3 encoding the degradation-targeting box where normally casein kinase 1 (CK1) first phosphorylates Ser45. This phosphorylation event primes for subsequent phosphorylation by glycogen synthase kinase-3b (GSK-3b) at Thr41, Ser37, and Ser33. The phosphorylation of these sites marks the protein for degradation by the proteasome system. An amino acid exchange at or adjacent to these sites leads to hindrance of b-catenin degradation, cytoplasmic accumulation and finally to translocation into the nucleus (17) . In contrast, BRAF V600E mutations were detected in 81-100% of PCP; this appears to be the critical event in the pathogenesis of this CP subgroup (11, 12, 16) .
Along with the rarity of mutations other than CTNNB1 and BRAF, previous studies on ACP showed no larger chromosomal imbalances. However, the results of these previous reports are inconsistent regarding focal amplifications or gene deletions (18) (19) (20) (21) (22) (23) (24) .
In this study, we investigated a large cohort of 121 ACP, mostly from pediatric patients, for b-catenin mutations and explored the possible prognostic and clinical significance of different CTNNB1 exon 3 mutations. We also determined whether mutated cases carry concomitant DDX3X (DEAD box helicase 3, X-linked) mutations because this gene was found mutated in 50% of medulloblastomas harboring CTNNB1 mutations (25) (26) (27) . Finally, we performed molecular inversion profiling (MIP) on 16 cases to investigate the possible presence of chromosomal aberrations that might play a role in the tumorigenesis of this challenging neoplasm.
MATERIALS AND METHODS

Patient Data and Statistical Analysis
A cohort of 121 ACP specimens from 117 patients (98 pediatric and 19 adult patients; median age at diagnosis: 10 years; 61 male and 56 female patients) and 16 PCP from 15 adult patients (median age at diagnosis: 50 years; 6 males, and 9 females) was analyzed. The histological material was retrieved from the archives at the Institute of Neuropathology, University of Bonn Medical Center, the German Brain Tumor Reference Center (Bonn, Germany), and the archives at the Department of Pathology, Catholic University of Sacred Heart (Rome, Italy). All tumors were classified according to the 2016 World Health Organization classification of CNS tumors (28) . All patients (or parents) gave informed consent to the study. The study adheres to the ethical guidelines of the involved institutions.
Eighty pediatric patients with ACP diagnosis were enrolled in the KRANIOPHARYNGEOM 2000/2007 studies of the Society of Paediatric Oncology and Haematology (GPOH). Clinical data including age, disease status at presentation, gender, extent of surgical resection, and event-free survival were collected. The mean follow-up of the patients was 4.4 6 2.5 years. Event-free survival was defined as the time period between date of diagnosis to date of first progression, relapse, death of any cause, or last visit. Statistical analyses were performed using SPSS 19.0 (SPSS, Inc., Chicago, IL). All variables used for analyses were nonparametric. Therefore, for comparison of 2 independent groups for a continuous variable the Mann-Whitney U test was used. For comparison of different groups for categorical variables the v 2 -test was used. Both tests are 2-tailed; p < 0.05 was chosen as significant. Survival analyses were performed using the KaplanMeier method (log-rank test) (29) .
Immunohistochemistry and DNA Extraction
Immunohistochemical analyses (IHC) were performed on a Ventana immunostainer Benchmark XT (Roche-Ventana, Darmstadt, Germany) with anti-b-catenin antibody clone 14 (MAb14) from BD Transduction Laboratories (Franklin Lakes, NJ) on formalin-fixed paraffin-embedded (FFPE) tissue slides.
DNA was obtained from 10-mm FFPE tissue slides using the QIAamp DNA Mini Tissue Kit (Qiagen, Düsseldorf, Germany) according to the manufacturer's instructions for 114 cases (99 ACPs and all 16 PCP). Selection of tumor areas was done following histological examination after IHC staining.
For 25 ACP cases, tumor material was obtained from hematoxylin and eosin (H&E)-stained slides with lasercapture microdissection (LCM; Veritas Microdissection Instrument 704, Arcturus, Life Technologies, Darmstadt, Germany). Twenty-two of these cases were chosen for LCM because of the low content of epithelial tumor cells in the specimens. DNA was extracted from 3 ACP cases using both methods to compare the results after QIAamp and LCM. In brief, LCM infrared laser was used to capture tumor cells from palisading epithelium and/or whorl-like nodules on a thermolabile polymer. In most cases, 4-8 of these regions were clearly visible and collected for LSM to capture as many of these regions as possible for LCM. DNA was extracted using Arcturus PicoPure DNA extraction kit following the manufacturer's instructions (Life Technologies). The extracted DNA was directly used for CTNNB1 exon 3 polymerase chain reaction (PCR).
CTNNB1 and DDX3X Sequencing
CTNNB1 exon 3 and DDX3X exons 9, 10, 11, 14, and 15 were amplified by PCR using the PyroMark PCR kit (Qiagen). Primers and conditions are shown in Table 1 . After evaluation of the size of the PCR products on 2% agarose gels, the products were purified using a PCR purification kit (Qiagen). Sanger sequencing reactions were performed in duplicate (forward and reverse) as custom service by Eurofins MWG Operon (Ebersberg, Germany) using 30 ng of the purified PCR product.
BRAF V600E Pyrosequencing
We screened the hotspot codon 600 (exon 15) of the BRAF gene for mutations using a pyrosequencing assay, as reported elsewhere in detail (30) . Briefly, a 122-bp fragment of exon 15 of BRAF containing the V600 coding region was amplified by PCR with PyroMark PCR kit (Qiagen) using 62.5 ng genomic DNA as template (Table 1) . PCR products were subjected to pyrosequencing using the sequencing primer 5 0 -AGGTGATTTTGGTCTAGCTACAG-3 0 with the nucleotide dispensation order A/T G A/G AT. As a positive control for the screening, DNA was used from SK-Mel 28 cells (HTB-72, ATCC) (LGC Standards, Wesel, Germany) that harbor a BRAF V600E mutation.
Next Generation Sequencing
The coding exons of CTNNB1 and 22 other genes (Table 2) identified by whole exome sequencing in a small pilot cohort of tumors as potential candidates (data not shown) were extracted using UCSC table browser (hg19) and submitted to Ion AmpliSeq Designer. The resulting custom design consists of 916 amplicons with average size of 195 bp. Ion AmpliSeq library kit 2.0 (Life Technologies) was used to prepare template DNA for sequencing. Four to 8 samples (8-16 libraries) were sequenced per run on Ion Torrent PGM instrument. The library templates were prepared for sequencing using the Life Technologies Ion OneTouch v2 DL protocols and reagents.
Sequencing was performed with the Ion PGM 200 Sequencing Kit (Life Technologies). The PGM sequencing data were processed using Ion Torrent Suite Software v3.0. See the Supplementary Data for more detailed information.
Molecular Inversion Profiling
To identify copy number gains and losses, we used an MIP array including 330,000 inversion probes (Version v2.0, Affymetrix, Santa Clara, CA). The MIP assay was performed as previously described (31) . The raw MIP data file was analyzed using the Nexus Copy Number 7.0 Discovery Edition software (BioDiscovery, El Segundo, CA). BioDiscovery's SNP-FASST2-Segmentation algorithm was used to make copy number and loss of heterozygosity calls. Genomic Identification of Significant Targets in Cancer (GISTIC) analysis was also used to distinguish significant chromosomal aberrations from random background (p-level: 0.05).
RESULTS
b-Catenin IHC, CTNNB1, DDX3X, and BRAF
Mutational Analysis
Although the staining patterns and amount of b-catenin accumulated nuclei differed widely, nuclear accumulation of b-catenin was present in at least a subpopulation of cells in all ACP specimens (Fig. 1A-C) . None of the PCP had nuclear accumulation of b-catenin. In our cohort of ACP specimens from 117 patients we found CTNNB1 mutations in 89 cases (76.1%). For 3 patients, tumor material of relapses was available (1 patient with 2 relapses, 2 patients with 1 relapse). Identical CTNNB1 mutations were found in the original tumor as well as in the relapses. None of the PCP had a mutation in CTNNB1 exon 3.
Fifty-three primary ACP cases had mutations at or adjacent to Ser33 (17x Asp32; 21x Ser33; 15x Gly34), 16 mutations were found at or adjacent to Ser37 (2x His36, 14x Ser37), and 17 cases showed mutations at Thr41 (Fig. 1D) . One case with a T41I mutation had an additional mutation at Pro44 (P44I). Only a single case harbored a Ser45 mutation. Short deletions were found in 2 cases, a 9-bp in-frame deletion around codons 30-33, and a 21-bp in-frame deletion spanning from codons 42 to 48. No CTNNB1 exon 3 mutations were found in 28 (23.9%) ACP cases (Supplementary  Data Table) .
DNA was extracted using a QIAamp extraction kit from most ACP cases (99 of 121 [117 patients]), and LCM was used for 25 cases with low content of epithelial tumor cells. It is noteworthy that only 12 of these 25 ACP cases showed CTNNB1 mutations. Therefore, 2 wild-type cases were reextracted after LCM from b-catenin-immunostained slides (instead of H&E). Subsequent Sanger sequencing confirmed the earlier results in both cases.
In 3 cases, DNA was extracted using both extraction methods and identical CTNNB1 mutations after QIAamp extraction from FFPE slides as well as after LCM from H&E stains were found (Supplementary Data Table) .
The analysis of DDX3X mutations was performed in 28 ACP, all harboring CTNNB1 mutations, but functional mutations were not found (not shown). Eighty-four ACP cases were screened for BRAF V600E mutations by pyrosequencing (58x) and next generation sequencing (NGS) (26x) of those 71 carrying CTNNB1 mutations, but no BRAF mutations were found. Conversely, 14 of the 15 PCP (93%) harbored BRAF V600E mutations ( Fig. 2A,  B ; Supplementary Data Table) . The patient of whom material of a relapse was available had a BRAF V600E mutation in the original tumor as well as in the relapse tissue.
NGS Analysis
In 26 ACP cases NGS was also performed, which confirmed the CTNNB1 exon 3 Sanger sequencing data in all but 4 cases. In 2 ACP lacking CTNNB1 mutations after Sanger sequencing, NGS revealed a D32Y mutation in 1 case and a frameshift deletion within codon 32 in the other case. The same deletion was also found by NGS in a case showing a D32G mutation after Sanger sequencing. Finally, instead of a G34E mutation NGS detected a W66L mutation in 1 case, which was not present in the Sanger sequencing result (Supplementary Data Table) . In all 4 discrepant cases, repeat Sanger sequencing confirmed the earlier Sanger sequencing results. NGS also confirmed the presence of the aforementioned double mutation (T41I and P44I). Besides the CTNNB1 mutations in ACP and BRAF V600E mutations in PCP, no further mutations were detectable by NGS in both CP subtypes.
Correlation of CTNNB1 Mutations with Clinical Outcome
Statistical analysis (v 2 -test) revealed no significant differences between pediatric (age at diagnosis <18 years) and adult ACP patients regarding CTNNB1 mutation frequency (p ¼ 0.135), even though only 2 of 19 adult cases were wildtype (10.5%), whereas 26 of 98 pediatric ACP lacked CTNNB1 mutations (26.5%). The comparison between male and female patients showed no differences (p ¼ 0.488; 13 of 61 males and 15 of 56 females without CTNNB1 mutation). In 80 pediatric ACP patients, clinical data were available from the German KRANIOPHARYNGEOM 2000/2007 trials including 20 cases without and 60 cases with CTNNB1 mutations. Of the latter, 40 had mutations at or adjacent to Ser33 (codons 32-34), 10 at or adjacent to Ser37 (codons 36-37), 9 at Thr41 (including the double mutated case), and 1 at Ser45.
Patient characteristics such as gender, age, tumor size, and location or physical function were not associated with outcome; this was also the case when CTNNB1 mutated cases were compared with wild-type cases and when the 5 mutational groups (no mutation, codons 32-34, codons 36-37, Thr41, and Ser45) were compared with each other (not shown). Furthermore, 3-and 6-year event-free survival rates showed no significant differences when mutated and wildtype cases were compared or in a comparison within the 5 groups. Interestingly, cases with mutations at Thr41 had the lowest event-free survival rate when compared among the 5 mutational groups. However, this finding did not reach statistical significance because only few Thr41-mutated cases were found (p ¼ 0.118, Thr41 vs Asp32-Gly34; Fig. 3B ).
When the 6-year event-free survival rates within the 5 groups were evaluated in regard to the degree of surgical resection (complete vs incomplete), no significant difference in survival was observed (not shown).
Whole Genome Copy Number Aberrations Analysis (MIP)
The MIP analysis of 14 ACP and 2 PCP revealed that larger chromosomal aberrations were absent in both types of CP. Although almost no gains or losses were detected for the PCP (data not shown), some ACP showed recurrent focal copy-number aberrations at least in subgroups of cases. MIP group 1 (5 female patients) showed a stable genome (like the PCP). In MIP group 2 (5 male patients) there was a recurrent loss at Xq28 (25 genes, eg L1CAM, DUSP9, or HAUS7); in MIP group 3 (1 male and 3 female patients) several recurrent focal gains were detected by GISTIC analysis at chromosomal loci 2p23.2 (BRE), 5q11.2 (ITGA2), 10p12.1-2 (KIAA1217), 10q26.12-13 (FGFR2), 13q12.12 (MIPEP and TNFRSF19), 17q21.2 (several keratin genes), and 21q21.1 (Linc00478). Some other loci containing genes such as FTO (3x, 16q12.2), JAG1 (3x, 20p12.2), or ATXN1 (3x, 6p22.3) also showed significant gains in this MIP group (Fig. 4) . Clinical data of only 11 of these ACP patients (5x group 1, 4x group 2 and 2x group 3) were available so that a survival analysis among these groups was not possible. In addition to the gender differences between MIP groups 1 and 2, group-wise comparison showed that all MIP group 2 patients (Xq28 loss) had events, whereas only 50%-60% of MIP group 1 and group 3 patients developed tumor progressions or recurrences (data not statistically significant).
DISCUSSION
Within the last decade, several groups reported of CTNNB1 mutations in ACP resulting in activation of WNT signaling (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , and these mutations appear to represent the driving force in the tumorigenesis. Evidence for this hypothesis also comes from in vivo experiments with a genetically engineered mouse model that developed sellar tumors that closely resemble human ACP by expressing a degradationresistant form of b-catenin in early progenitor cells of Rathke's pouch (32, 33) .
ACP showing nuclear b-catenin accumulation but lacking CTNNB1 mutations have also been found, and the mutation rate of 76.1% we report here in this largest cohort of mostly pediatric ACP analyzed for CTNNB1 mutations to date is in concordance with most other publications. Three groups found CTNNB1 mutations in all of their analyzed tumor samples but those sample sizes were rather small (10 and 8 cases of ACP, respectively) (7, 13), or contained mainly adult ACP (56 of 79) (16) . On the other hand, one initial study found a mutation rate of only 16% (7 of 43 ACP) (10) . Indeed, all other publications reported mutation rates between 50% and 77% (5, 6, 8, 9, 12, 14, 15), except for Brastianos et al, who recently used a new method (MuTect) to detect somatic mutations with very low allelic frequencies and found mutations in 62 of 65 ACP (95%) (11) . Based on this study and the aforementioned recent publication by Hoelsken et al with mainly adult ACP (16), we assume that the real frequency of CTNNB1 mutated ACP cases could be even higher than 76.1%; further mutations in our large cohort were not detectable by Sanger sequencing from FFPE-derived DNA.
ACP are often heterogeneous tumors and, therefore, mutations might only be found in a subset of sequenced cells (11) , which can make it very difficult to identify mutations in the electropherogram. Furthermore, Kato et al showed that the surrounding stroma did not harbor mutations (6) . In contrast, Sekine et al found identical mutations in tumor cells and surrounding mesenchymal tissue (7). Brastianos et al reported that the mutations were clonal and should be present in all tumor cells (11) , while an older publication showed that only a subset of CP are monoclonal in origin (34) . In this context, Hoelsken et al found that CTNNB1 mutations were present in b-catenin-accumulating and nonaccumulating tumor cells (13) . Notably, however, the latter work found different CTNNB1 exon 3 mutations in the nonaccumulating tumor cells and in the corresponding accumulating cells in 50% of the analyzed samples.
Besides technical limitations, partly degraded FFPEderived DNA and tumor heterogeneity are possible causes leading to the low percentage of CTNNB1 mutations, especially when using LCM (compared with the presence of nuclear b-catenin accumulation in all cases). Another reason could be the existence of larger deletions that cannot be detected by Sanger sequencing from FFPE-derived DNA. Such deletions have been reported, for example, in hepatoblastomas (35) . Such deletions have also been described in a single ACP case (16) , but shorter deletions within exon 3 occur, as we have shown here, confirming previous reports by other groups in single cases (5, 11, 16) ; these also exist in hepatoblastomas (35) . APC or AXIN1/2 mutations or deletions have not previously been described as an alternate cause of activated WNT signaling in ACP but can be found in WNT-activated medulloblastomas and hepatoblastomas (36) (37) (38) (39) (40) (41) . However, no copy number losses or copy neutral losses of heterozygosity were found by MIP, which argues against the involvement of these WNT components.
Nearly all point mutations detected in our cohort have been published before in ACP. Only the P44I (additionally present in a T41I mutated sample) mutation has not been previously described in ACP or in the COSMIC (Catalogue of Somatic Mutations in Cancer; www.cancer.sanger.ac.uk) database. The presence of multiple mutations within exon 3 is also sporadically described before in ACP (5, 11, 13, 15, 16) ; however, this seems to be a rare event.
While the presence of CTNNB1 mutations in ACP was already known, we used the results from our large cohort to evaluate for the first time whether outcome differences in patients with ACP with mutations at the different phosphorylation sites in exon 3 exist. We found a trend towards a worse 6-year event-free survival in patients with mutations at Thr41, although this difference was not statistically significant. Similar studies have been performed in aggressive fibromatosis (AF), and desmoid tumors (DT), where patients with mutations at Ser45 (especially S45F) presented with higher recurrence rates than those with mutations at Thr41 (42) (43) (44) (45) , while another study on DT could not find a significant outcome difference (46) . As for these extracranial neoplasms almost no other than these 2 mutation sites have been described, it could be hypothesized that more C-terminal mutations lead to higher recurrence rates. Mutations at Ser45 are very rare in ACP but the single case in our cohort indeed showed an early event. As the phosphorylation at Ser45 by CK-1 represents the first event in the b-catenin degradation process, followed by phosphorylation of Thr41, Ser37, and Ser33 by GSK-3b, in that sequential order (45) , this phosphorylation order could be a reason for the more aggressive phenotype in more C-terminal mutated ACP, AF, and DT cases. Supporting this point of view, Maher et al found that specific point mutations at different phosphorylation sites can exert variable effects on b-catenin function potentially explaining the different clinical behavior (47) . However, this hypothesis remains speculative and, moreover, our present findings on ACP need to be confirmed in even larger cohorts before a recommendation for intensified postoperative therapy in patients with mutations at Thr41 (and possibly Ser45) might be discussed. To our knowledge, other tumor entities such as hepatoblastoma or medulloblastoma that are known to harbor CTNNB1 exon 3 mutations have not been analyzed like this before. However, for medulloblastomas, it is known that patients with CTNNB1 mutations belonging to the WNT subgroup have an excellent prognosis, but in this tumor entity almost all mutations can be found at or adjacent to Ser33 or Ser37 (48) .
Whole exome sequencing in 12 ACP and 3 PCP by Brastianos et al detected only few isolated mutations other than CTNNB1 (ACP) and BRAF (PCP), and these may only be passenger mutations (11) , which is in agreement with our search for further mutations by NGS and Sanger sequencing of the DDX3X gene. Also, other groups could not find further mutations in postulated candidate genes for tumor initiation or progression, for example, PTCH1 or TP53 (34, 49) .
A coexistence of CTNNB1 and BRAF V600E mutations in ACP as found by Larkin et al (12) in 12.5% of ACP (2 of 16) was not detectable in our cohort. However, PCP showed the expected BRAF mutation in almost all cases, which is in agreement with all other publications (11, 12, 16, 50) , and clearly represents a major pathogenic event in this CP subgroup. Because we found a clear difference between ACP and PCP in terms of mutational status of CTNNB1 and BRAF, we propose that mutational screening would be a helpful tool for establishing differential diagnosis.
Because ACP without CTNNB1 mutations and PCP without BRAF mutations have been reported, we used the MIP assay to search for chromosomal aberrations present in CP that can additionally lead to tumor initiation and/or progression. MIP technology was chosen because this probe hybridization-based method is applicable for the analysis of FFPE-derived highly fragmented DNA, in contrast to whole genome/exome sequencing or SNP arrays, which in principle have a higher coverage but do not give sufficient results with fragmented DNA (51) . While larger chromosomal aberrations [eg monosomy 6 in WNT subgroup medulloblastomas (48)] were not detectable in ACP or PCP, the findings of recurrent focal gains or deletions in subgroups of ACP may give new insights into possible mechanisms leading to ACP initiation and/or progression. However, further research has to be done to find out if these chromosomal aberrations alone might be sufficient for tumor development. Furthermore, it would be important to know which genes in the Xq28 region or amplified in MIP group 3 have an impact on tumorigenesis, tumor cell migration or recurrence. To find out if one of the MIP groups indicates a less favorable event-free survival rate, cohort sizes need to be larger to reach statistical significances.
In conclusion, we provide further evidence that CTNNB1 mutations for ACP and BRAF mutations for PCP are the main driving forces in tumorigenesis of the 2 CP subgroups and show for the first time a trend towards a shorter event-free survival in ACP with mutations at Thr41. Furthermore, we identified 3 ACP groups by MIP assay with distinct chromosomal alterations and found several aberrant gene loci which might help to identify new mechanisms participating in tumorigenesis and can possibly be exploited as therapeutic targets in the future.
